TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00396305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sterile phosphate buffered saline solution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Inactivated Influenza
Description: The trivalent influenza vaccine is a sterile suspension prepared from the allantoic fluids of chicken embryos infected with a specific type of influenza virus. Each 0.5 mL dose of the vaccine contains 15 mcg hemagglutinin (HA) of 3 strains of virus (H1N1, H3N2, and B). The vaccine is a liquid preparation; as such, no diluent is required. It is essentially clear and slightly opalescent in color.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Inactivated Influenza
Description: The trivalent influenza vaccine is a sterile suspension prepared from the allantoic fluids of chicken embryos infected with a specific type of influenza virus. Each 0.5 mL dose of the vaccine contains 15 mcg hemagglutinin (HA) of 3 strains of virus (H1N1, H3N2, and B). The vaccine is a liquid preparation; as such, no diluent is required. It is essentially clear and slightly opalescent in color.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Inactivated Influenza
Description: The trivalent influenza vaccine is a sterile suspension prepared from the allantoic fluids of chicken embryos infected with a specific type of influenza virus. Each 0.5 mL dose of the vaccine contains 15 mcg hemagglutinin (HA) of 3 strains of virus (H1N1, H3N2, and B). The vaccine is a liquid preparation; as such, no diluent is required. It is essentially clear and slightly opalescent in color.
Study: NCT00701246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferrous sulfate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ferrous sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferrous sulfate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ferrous sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (folic acid)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (folic acid)
Study: NCT00865046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periosteal stimulation
Description: Four acupuncture needles are placed around the knee to the level of the periosteum and two needles are placed pretibially in the soft tissue. All needles are stimulated with 100 Hz current. The stimulation of the needles in the soft tissue is discontinued after one minute.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Periosteal stimulation
Description: Four acupuncture needles are placed around the knee to the level of the periosteum and two needles are placed pretibially in the soft tissue. All needles are stimulated with 100 Hz current. The stimulation of the needles in the soft tissue is discontinued after one minute.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control-Periosteal Stimulation
Description: Acupuncture needles are placed as per the PST intervention, but only the soft tissue needles receive electrical stimulation for one minute.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control-Periosteal Stimulation
Description: Acupuncture needles are placed as per the PST intervention, but only the soft tissue needles receive electrical stimulation for one minute.
Study: NCT03892707

Intervention type: DRUG
Intervention: Exposure of interest (within routine clinical practice):Vitamin B complexes Milgamma® and Milgamma® compositum
Description: Milgamma®: 2 mL injection solution containing thiamin hydrochloride 100 mg, pyridoxine hydrochloride 100 mg, cyanocobalamin 1 mg, lidocaine hydrochloride 20 mg.~Milgamma® compositum: 1 tablet containing benfotiamine 100 mg, pyridoxine hydrochloride 100 mg.
Study: NCT02820688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine 1%

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular Nerve Block
Description: Ultrasound guided infraclavicular nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular Nerve Block
Description: Ultrasound guided infraclavicular nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular Nerve Block
Description: Ultrasound guided infraclavicular nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.167%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.125%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine 0.66%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine 0.5%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: All nerve blocks will be performed with ultrasound guidance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: All nerve blocks will be performed with ultrasound guidance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: All nerve blocks will be performed with ultrasound guidance
Study: NCT00194727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
Study: NCT00318370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farletuzumab
Description: Weekly Farletuzumab infusions Dose dependent on dosing group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemo Plus Far
Description: Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
Study: NCT05933798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICOPE
Description: The ICOPE approach with locally adapted care pathways was implemented by trained integrated care managers (ICMs) advised by multi-disciplinary teams, delivered in primary care settings

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in the Control Group would have their care plan after assessment and seek health and care services as usual without additional advice or support on implementing the care plan
Study: NCT02275520

Intervention type: DEVICE
Group type: OTHER
Intervention: NIO Adult device
Description: IO access-1

Intervention type: DEVICE
Group type: OTHER
Intervention: Bone Iniection Gun
Description: IO access-2

Intervention type: DEVICE
Group type: OTHER
Intervention: EZ-IO
Description: IO access-3

Intervention type: DEVICE
Group type: OTHER
Intervention: Jamshidi Intraosseous Needle
Description: IO access-4

Intervention type: DEVICE
Group type: OTHER
Intervention: Cook Intraosseous Needle
Description: IO access-5
Study: NCT01873807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDA
Description: Idarubicin: 15mg/m2/d: -8-\>-6d

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TBI
Description: TBI: 4.5 Gy/d, -5d, -4d

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: TBI
Description: TBI: 4.5 Gy/d, -5d, -4d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX
Description: CY:60mg/kg/d, -3d, -2d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTX
Description: CY:60mg/kg/d, -3d, -2d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16
Description: VP-16: 15mg/kg, -2d, -1d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VP-16
Description: VP-16: 15mg/kg, -2d, -1d
Study: NCT02938507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 1 solabegron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 2 solabegron
Study: NCT02448914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIGEL
Description: All patients will receive TRIGEL. Treatment order is determined by randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIGEL
Description: All patients will receive TRIGEL. Treatment order is determined by randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duodopa
Description: All patients will receive Duodopa. Treatment order is determined by randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duodopa
Description: All patients will receive Duodopa. Treatment order is determined by randomization.
Study: NCT04707378

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation(rTMS)
Description: Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation(rTMS)
Description: Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
Study: NCT01405378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot therapy and transcranial direct current stimulation
Description: Administration of Robot Therapy:~Therapy will be administered by making use of the Armeo Robot. Sessions will involve high-intensity, repetitive, task-oriented movements directed by video screens. Administration of tDCS:~Anodal tDCS will be administered using a CE marked transcranial Direct Current Stimulator (Newronika Italy). Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Robot therapy and transcranial direct current stimulation
Description: Administration of Robot Therapy:~Therapy will be administered by making use of the Armeo Robot. Sessions will involve high-intensity, repetitive, task-oriented movements directed by video screens. Administration of tDCS:~Anodal tDCS will be administered using a CE marked transcranial Direct Current Stimulator (Newronika Italy). Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2).
Study: NCT02480504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention intermittent energy restriction
Description: Randomized clinical trial

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous energy restriction
Study: NCT03983460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Each single used prefilled syringe contains 300 mg of Dupilumab in 2 mL solution (150mg/mL) Dupilumab is a fully human monoclonal antibody against interleukin (IL)-4 receptor alpha that inhibits IL-4/IL-13 signaling, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimized TCS treatment
Description: Application of betamethasone valerate 0.1% (Betneval 0.1% cream), a potent topical corticosteroid, and if not active, application of clobetasol propionate 0.05% (Dermoval 0.05% cream), a very potent topical corticosteroid. TCS treatment will be associated with a personal therapeutic education for treatment optimization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies
Description: Four skin biopsies (5 mm diameter) and ten microbiopsies (2 \& 3 mm diameter) will be performed according the following schedule:~* Day 0~  * a 5 mm section biopsy from a non-lesional skin~ * a 5 mm section biopsy from an active lesion~ * a 3 mm section microbiopsies from a non-lesional skin~ * a 3 mm section microbiopsies from an active lesion~ * a 2 mm section microbiopsies from a non-lesional skin~ * a 2 mm section microbiopsies from an active lesion~* Day 28~  * a 5 mm section biopsy on improved/healed lesion~ * a 3 mm section microbiopsies on improved/healed lesion~ * a 2 mm section microbiopsies from non lesional skin identified at V1~ * a 2 mm section microbiopsies on improved/healed lesion~* Day 168~  * a 5 mm section biopsy on improved/healed lesion~ * a 3 mm section microbiopsies on improved/healed lesion~ * a 2 mm section microbiopsies from non-lesional skin identified at V1~ * a 2 mm section microbiopsies on improved/healed lesion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsies
Description: Four skin biopsies (5 mm diameter) and ten microbiopsies (2 \& 3 mm diameter) will be performed according the following schedule:~* Day 0~  * a 5 mm section biopsy from a non-lesional skin~ * a 5 mm section biopsy from an active lesion~ * a 3 mm section microbiopsies from a non-lesional skin~ * a 3 mm section microbiopsies from an active lesion~ * a 2 mm section microbiopsies from a non-lesional skin~ * a 2 mm section microbiopsies from an active lesion~* Day 28~  * a 5 mm section biopsy on improved/healed lesion~ * a 3 mm section microbiopsies on improved/healed lesion~ * a 2 mm section microbiopsies from non lesional skin identified at V1~ * a 2 mm section microbiopsies on improved/healed lesion~* Day 168~  * a 5 mm section biopsy on improved/healed lesion~ * a 3 mm section microbiopsies on improved/healed lesion~ * a 2 mm section microbiopsies from non-lesional skin identified at V1~ * a 2 mm section microbiopsies on improved/healed lesion
Study: NCT03599271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-Coated Device
Description: 3000 mcg mometasone furoate-coated sinus dilation device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-Coated Device
Description: 3000 mcg mometasone furoate-coated sinus dilation device
Study: NCT03983460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin prick-test
Description: Skin prick test is a method for medical diagnosis of allergy consisting in introducing a small amount of an allergen into the patient's skin. The allergen penetrates the epidermis by pricking the skin with a pin.~Skin Prick test for Derp and Derf will be performed at Day 0, preferentially on the forearms, avoiding lesional areas.~For the results interpretation, the two allergen Derp/Derf will be compared to 2 controls:~* Negative control : saline solution~* Positive control : histamine solution~Positive criteria of prick tests results are:~* Positive control's diameter ≥ 3mm~* And negative control's diameter \< 3 mm~* And tested allergen with wheal ≥ positive control, i.e. 3mm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin prick-test
Description: Skin prick test is a method for medical diagnosis of allergy consisting in introducing a small amount of an allergen into the patient's skin. The allergen penetrates the epidermis by pricking the skin with a pin.~Skin Prick test for Derp and Derf will be performed at Day 0, preferentially on the forearms, avoiding lesional areas.~For the results interpretation, the two allergen Derp/Derf will be compared to 2 controls:~* Negative control : saline solution~* Positive control : histamine solution~Positive criteria of prick tests results are:~* Positive control's diameter ≥ 3mm~* And negative control's diameter \< 3 mm~* And tested allergen with wheal ≥ positive control, i.e. 3mm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: A 50ml blood sample will be collected by venipuncture at Day 0, Day 28 and Day 168.~More specifically a 40 ml blood sample will be drawn on heparinized tubes for immunophenotyping and a 10 mL on serum blood collection tube for analysis of AD biomarkers by mass cytometry and ELISA.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample collection
Description: A 50ml blood sample will be collected by venipuncture at Day 0, Day 28 and Day 168.~More specifically a 40 ml blood sample will be drawn on heparinized tubes for immunophenotyping and a 10 mL on serum blood collection tube for analysis of AD biomarkers by mass cytometry and ELISA.
Study: NCT01227720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Nicotine Replacement Therapy (NRT) 2 mg
Description: 2 mg Single-dose of new NRT product (NSL2L)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Nicotine Replacement Therapy (NRT)
Description: 4 mg Single-dose of new NRT product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Nicotine Replacement Therapy (NRT)
Description: 4 mg Single-dose of new NRT product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Nicotine Replacement Therapy (NRT)
Description: 4 mg Single-dose of new NRT product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Nicotine Lozenge
Description: 2 mg Single-dose of marketed lozenge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Nicotine Lozenge
Description: 4 mg Single-dose of marketed lozenge
Study: NCT01268904

Intervention type: DRUG
Intervention: Valproate
Description: Intravenous valproate application to pediatric patients suffering from status epilepticus and acute repetitive seizures
Study: NCT02853149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spinal Cord Injury (SCI)
Description: The SCI Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver Intervention(CCC)
Description: The Caregiver Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Caregiver Control (CC)
Description: The Caregiver Control group will also discuss ways in which health and fitness can be improved through exercise and nutrition and will also be offered a fully paid membership to the an exercise fitness center to encourage them to exercise and consume a healthy diet. Unlike the Caregiver Intervention group(CCC) the lifestyle recommendations will be provided by internet authorities such as Web Medical(WebMD), the US Department of Agriculture, and the US Department of Human Health Services, which are dependable websites that promote healthy ways of living.
Study: NCT02089503

Intervention type: OTHER
Intervention: intravitreal injections of Lucentis
Description: intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use

Intervention type: OTHER
Intervention: intravitreal injections of Lucentis
Description: intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use

Intervention type: OTHER
Intervention: intravitreal injections of Lucentis
Description: intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use
Study: NCT06792409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally invasive breast augmentation procedure with a trans-axillary approach.
Description: Minimally invasive breast augmentation procedure with a transaxillary approach using Motiva Ergonomix2 Diamond®, Motiva Injector® and Motiva® Inflatable Balloon.
Study: NCT01817660

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open repair of popliteal artery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular repair of popliteal artery
Study: NCT03599271

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Device
Description: Sinus dilation device without drug
Study: NCT03580083

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-111
Description: Recombinant adeno-associated virus serotype 9 capsid containing α-L-iduronidase expression cassette

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-111
Description: Recombinant adeno-associated virus serotype 9 capsid containing α-L-iduronidase expression cassette
Study: NCT00882063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P276-00
Description: Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.Starting dose level of P276-00 is 50 mg/m2/day to be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min from day 1 to day 5 every 21 days. This constitutes one cycle of P276-00. Six such cycles will be administered to subjects.
Study: NCT03568695

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Two samples on each of the three sites (pharynx, rectum, urine)
Description: two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .
Study: NCT01090674

Intervention type: OTHER
Intervention: No intervention
Description: We perform in all patients respiratory functional tests, thoracic x-ray, SNIF test and diaphragmatic magnetic resonance imaging.
Study: NCT01779804

Intervention type: PROCEDURE
Intervention: OFAR
Description: OFAR